Eli Lilly Says Zepbound (Tirzepatide) 2.5 Mg And 5 Mg Single-dose Vials Are Available For Self-Pay For Patients With An On-label Prescription
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly has announced that Zepbound (Tirzepatide) 2.5 mg and 5 mg single-dose vials are now available for self-pay patients with an on-label prescription. The pricing is competitive, being less than half the list price of other incretin medicines for obesity.
August 27, 2024 | 10:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's introduction of competitively priced Zepbound vials for self-pay patients could boost sales and market share in the obesity treatment market.
The availability of Zepbound at a lower price point could attract more self-pay patients, increasing Eli Lilly's sales and market share in the obesity treatment market. This move aligns with their savings program, making it a strategic decision to enhance competitiveness.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90